Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 14926 - 14950 of 15251 in total

3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one

Experimental

5-{[1-(2-fluorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine

Experimental

N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE

Experimental

6-amino-2-[(thiophen-2-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one

Experimental

GDC-0349

GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.
Investigational

2,4-Diamino-5-Methyl-6-[(3,4,5-Trimethoxy-N-Methylanilino)Methyl]Pyrido[2,3-D]Pyrimidine

Experimental

CRA_1144

Experimental

N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide

Experimental

N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine

Experimental

N-(3-AMINOPROPYL)-2-NITROBENZENAMINE

Experimental

CRx-401

CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been...
Investigational
Matched Description: … lipid profiles, and this dose has proven to be well tolerated in clinical trials. ... in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and …

Albendazole oxide

Experimental

A-98881

Experimental

N-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide

Experimental

2,4-Diamino-6-[N-(2',5'-Dimethoxybenzyl)-N-Methylamino]Quinazoline

Experimental

1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol

Experimental

2,6-Diamino-8-(2-Dimethylaminoethylsulfanylmethyl)-3h-Quinazolin-4-One

Experimental

4-(2-amino-1,3-thiazol-4-yl)phenol

Experimental

3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one

Experimental

1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA

Experimental

1-(2-HYDROXYETHYLOXYMETHYL)-6-PHENYL THIOTHYMINE

Experimental

5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione

Experimental

2-(6-HYDROXY-1,3-BENZOTHIAZOL-2-YL)-1,3-THIAZOL-4(5H)-ONE

Experimental

GO-203-2C

GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Iupac: … hydroxypentylidene]amino}-1-hydroxypentylidene]amino}-1-hydroxyhexylidene]amino}-3-(C-hydroxycarbonimidoyl)propanoic acid …

OSI-7904L

OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA). Current treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.
Investigational
Matched Description: … liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and …
Displaying drugs 14926 - 14950 of 15251 in total